ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Treat Cancer, But Protect Heart Anderson Cardiologists Warn

July 30, 2004

Study: Women at Higher Risk Of Estrogen Receptor Positive Breast Cancer After Smoking

February 28, 2014

FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.

March 16, 2007

In Congress: Clinton Backs Genetic Privacy Bills, But Plans Changes Proposals

July 18, 1997

NCCS Networker Volume 2 Issue 3, Summer 1988

June 13, 1988

NCI blocked groups from phase III Iressa studies.

April 30, 2004